Core Viewpoint - Nxera Pharma has submitted a marketing authorisation application for daridorexant in South Korea, targeting the treatment of insomnia in adults, following successful Phase 3 trial results [1][9]. Group 1: Company Overview - Nxera Pharma is a biopharmaceutical company focused on developing specialty medicines for unmet medical needs, with operations in Japan, the UK, Switzerland, and South Korea [13]. - The company has a partnership with Shionogi for the commercialization of daridorexant in Japan, where it is marketed as QUVIVIQ® [3][13]. Group 2: Product Information - Daridorexant is a dual orexin receptor antagonist designed to treat insomnia by reducing overactive wake signals, and it has shown efficacy in improving subjective total sleep time, sleep onset latency, and wake after sleep onset in clinical trials [9][12]. - The Phase 3 trial demonstrated significant improvements in sleep metrics, with p-values less than 0.0001 for the primary and secondary endpoints compared to placebo [12]. Group 3: Market Context - Insomnia affects approximately 15-25% of the adult population in South Korea, translating to about 6.5-11 million individuals [2][7]. - The number of chronic insomnia patients treated in South Korea has increased by 21% from 2018 to 2022, indicating a growing market for insomnia treatments [7].

Core Insights - Nxera Pharma has announced positive top-line results from a Phase 3 study of daridorexant 50 mg for treating insomnia in South Korea, with plans to submit a marketing authorization application in Q1 2026 and expected approval in Q1 2027 [1][7] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet needs, operating in Japan and globally, and listed on the Tokyo Stock Exchange [12] - The company has established a commercial presence in Japan and is advancing an extensive pipeline through its unique drug discovery platform [12] Product Information - Daridorexant is a dual orexin receptor antagonist approved in Japan as QUVIVIQ® and is marketed in various regions including the US, Canada, and Europe [2][7] - The Phase 3 trial demonstrated significant improvements in subjective total sleep time, sleep onset latency, and wake after sleep onset compared to placebo, with p-values less than 0.0001 [5][7] Market Context - Insomnia affects approximately 15-25% of the adult population in South Korea, translating to about 6.5-11 million individuals, with a notable increase in chronic insomnia patients from 597,529 in 2018 to 722,440 in 2022 [3][10] - The condition is particularly prevalent among women and older adults, with 50% of treated patients aged 60 or above [10] Clinical Study Details - The Phase 3 trial was a multicenter, randomized, double-blind, placebo-controlled study involving adult and elderly patients, with participants receiving either daridorexant 50 mg or placebo for 28 days [4][5] - The incidence of treatment-emergent adverse events was similar between the daridorexant and placebo groups, reported at 13.41% and 14.81% respectively [5]

Core Insights - Nxera Pharma reported strong progress in the first half of 2025, with increasing revenues from its marketed products PIVLAZ® and QUVIVIQ®, and advancements in partnered programs [2][3][6] Operational Highlights - PIVLAZ® revenue increased by 7.6% from JPY 5,393 million to JPY 5,805 million compared to the prior corresponding period [6] - QUVIVIQ® generated JPY 1,586 million in revenue for the first half of 2025, with no sales in the prior corresponding period due to its launch in Q4 2024 [6] - Neurocrine Biosciences initiated Phase 3 trials for NBI-'568, resulting in a US$15 million payment to Nxera [6] - Nxera achieved a US$4.8 million milestone payment from Centessa Pharmaceuticals for the initiation of clinical development of ORX142 [6] Financial Highlights - Total revenue for the first half of 2025 was JPY 15,094 million (US$101.6 million), an increase of JPY 2,374 million (US$18.0 million) compared to the prior corresponding period [11] - R&D expenses rose to JPY 7,474 million (US$50.3 million), reflecting increased investment in R&D and currency impact [11] - SG&A expenses decreased to JPY 7,566 million (US$51.0 million), primarily due to targeted cost savings [11] - Operating loss improved to JPY 2,756 million (US$18.5 million) from JPY 3,654 million (US$24.0 million) in the prior corresponding period [11] - Net loss decreased to JPY 3,137 million (US$21.1 million) from JPY 4,703 million (US$30.9 million) in the prior corresponding period [11] - Cash and cash equivalents as of 30 June 2025 were JPY 32,997 million (US$228.1 million), an increase of JPY 729 million (US$22.3 million) from the beginning of the year [11] Pipeline and Future Outlook - Nxera is advancing a proprietary pipeline targeting obesity and chronic weight management, with over 30 active programs [5][10] - The company is well-positioned for significant value delivery for patients and shareholders with multiple key data readouts and new studies expected in the second half of 2025 [3][10]

Core Insights - Nxera Pharma has made significant progress since its transformation from Sosei Heptares, aiming to lead biopharmaceutical innovation in Japan and globally [2][3] - The company anticipates 2025 to be a pivotal year with key data readouts from multiple clinical trials and new studies commencing [3] Operational Highlights - Neurocrine initiated a Phase 3 program for NBI-1117568 targeting schizophrenia, supported by positive Phase 2 data [5] - Nxera assigned rights for cenerimod to Viatris, receiving an upfront payment of US$10 million, with additional milestone and royalty potential [6] - An agreement was signed with Holling Bio-Pharma for the commercialization of daridorexant in Taiwan, with a potential launch in 2026 [6] - Clinical development plans for partnered muscarinic agonists include multiple Phase 2 and Phase 3 studies scheduled for 2025 [6] Financial Highlights - Revenue for Q1 2025 totaled JPY 6,644 million (US$43.5 million), an increase of JPY 2,033 million (US$12.5 million) year-over-year, primarily due to the launch of QUVIVIQ® and an R&D milestone event [11] - R&D expenses rose to JPY 3,808 million (US$25.0 million), reflecting increased investment and the impact of a weaker Yen [11] - Operating loss improved to JPY 2,193 million (US$14.4 million) from JPY 3,076 million (US$20.7 million) in the prior year [11] - Net loss decreased to JPY 760 million (US$5.0 million) from JPY 3,281 million (US$22.1 million) in the previous year [11] - Cash and cash equivalents as of 31 March 2025 were JPY 34,465 million (US$230.0 million), an increase of JPY 2,197 million (US$24.3 million) since the beginning of the year [11] Corporate Developments - New appointments to the Board of Directors include Ms. Naoko Shimura and Ms. Nicola Rabson as External Directors [6] - Mr. Kiyoshi Kaneko was appointed Chief Commercial Officer, and Ms. Mariko Nakafuji was promoted to Chief Legal Officer [11] Pipeline and Strategy - Nxera is advancing over 30 active programs from discovery to late clinical stages, focusing on neurology, metabolic diseases, and immunology [10][12] - The company aims to address major unmet needs in rapidly growing medical areas, leveraging its NxWave™ discovery platform [10][12]